新闻源 财富源

2019年10月16日 星期三

康缘药业(600557)公告正文

康缘药业:2012年半年度报告摘要

公告日期:2012-08-11

   江苏康缘药业股份有限公司 (股票代码:600557)                2012 年半年度报告摘要




                       江苏康缘药业股份有限公司

                          2012 年半年度报告摘要


§1 重要提示

    1.1 本公司董事会、监事会及董事、监事、高级管理人员保证本报告所载资料不存在任
何虚假记载、误导性陈述或者重大遗漏,并对其内容的真实性、准确性和完整性承担个别及
连带责任。

    本半年度报告摘要摘自半年度报告全文,投资者欲了解详细内容,应当仔细阅读半年度
报告全文。

    1.2 公司全体董事出席董事会会议。

    1.3 公司半年度财务报告未经审计。

    1.4 是否存在被控股股东及其关联方非经营性占用资金情况?
    否

    1.5 是否存在违反规定决策程序对外提供担保的情况?
    否

    1.6 公司负责人肖伟、主管会计工作负责人陈友龙及会计机构负责人(会计主管人员)
焦晓杉声明:保证半年度报告中财务报告的真实、完整。


§2 公司基本情况

    2.1 基本情况简介

      股票简称                                          康缘药业
      股票代码                                          600557
  股票上市交易所                                    上海证券交易所
                                  董事会秘书                           证券事务代表
       姓名                         程 凡                                  解金亮
     联系地址        江苏省连云港市新浦区海昌南路 58 号     江苏省连云港市新浦区海昌南路 58 号
       电话                     0518-85521990                          0518-85521990
       传真                     0518-85521990                          0518-85521990
     电子信箱                  chf@kanion.com                         fzb@kanion.com




                                     第 1 页 共 20 页
            江苏康缘药业股份有限公司 (股票代码:600557)                  2012 年半年度报告摘要


            2.2 主要财务数据和指标

            2.2.1 主要会计数据和财务指标
                                                                            单位:元 币种:人民币
                                                                                      本报告期末比上年
                                               本报告期末             上年度期末
                                                                                        度期末增减(%)
         总资产                              2,760,265,595.88       2,581,406,604.69               6.93
         所有者权益(或股东权益)            1,474,919,051.08       1,435,872,808.83               2.72
         归属于上市公司股东的每股净
                                                            3.548              3.393                   4.57
         资产(元/股)
                                                                                          本报告期比上年
                                            报告期(1-6 月)          上年同期
                                                                                            同期增减(%)
         营业利润                              116,336,569.53        111,334,071.20                   4.49
         利润总额                              122,737,282.83        117,002,218.28                   4.90
         归属于上市公司股东的净利润            103,469,558.19         96,715,431.24                   6.98
         归属于上市公司股东的扣除非
                                               118,257,501.71         92,398,929.71                   27.99
         经常性损益的净利润
         基本每股收益(元)                                   0.25                  0.23                 8.70
         扣除非经常性损益后的基本每
                                                            0.28                  0.22                27.27
         股收益(元)
         稀释每股收益(元)                                0.25                  0.23                    8.70
         加权平均净资产收益率(%)                         6.97                  7.71      减少 0.74 个百分点
         经营活动产生的现金流量净额            103,945,902.68         10,052,527.15                  934.03
         每股经营活动产生的现金流量
                                                            0.25                  0.02             1,150.00
         净额(元)

            2.2.2 非经常性损益项目
            √适用 □不适用
                                                                          单位:元 币种:人民币
                       非经常性损益项目                                           金额
         非流动资产处置损益                                                                  -263,409.43
         计入当期损益的政府补助,但与公司正常经营业务密
         切相关,符合国家政策规定、按照一定标准定额或定                                       6,997,716.72
         量持续享受的政府补助除外
         除上述各项之外的其他营业外收入和支出                                               -24,153,006.78
         所得税影响额                                                                         2,616,942.80
         少数股东权益影响额(税后)                                                              13,813.17
                             合 计                                                          -14,787,943.52


        §3 股本变动及股东情况

            3.1 股份变动情况表
            √适用 □不适用
                                                                                         单位:股
                                 本次变动前            本次变动增减(+,-)            本次变动后
                               数量      比例(%)          其他         小计            数量       比例(%)
一、有限售条件股份          116,139,579     27.44      -7,600,000 -7,600,000        108,539,579     26.11
1、国家持股

                                              第 2 页 共 20 页
              江苏康缘药业股份有限公司 (股票代码:600557)                2012 年半年度报告摘要


 2、国有法人持股
 3、其他内资持股              116,139,579       27.44    -7,600,000   -7,600,000       108,539,579       26.11
 其中:境内非国有法人持股     108,539,579       25.64                                  108,539,579       26.11
     境内自然人持股             7,600,000        1.80    -7,600,000   -7,600,000                 0           0
 4、外资持股
 其中:境外法人持股
     境外自然人持股
 二、无限售条件流通股份       307,107,112       72.56                                  307,107,112      73.89
 1、人民币普通股              307,107,112       72.56                                  307,107,112      73.89
 2、境内上市的外资股
 3、境外上市的外资股
 4、其他
 三、股份总数                 423,246,691      100.00    -7,600,000   -7,600,000       415,646,691     100.00

              3.2 股东数量和持股情况
                                                                                           单位:股
报告期末股东总数                                                                                      17,380 户
                                             前十名股东持股情况
                                             持股                     报告期内       持有有限售条    质押或冻结
          股东名称             股东性质                持股总数
                                             比例                       增减           件股份数量    的股份数量
                               境内非国
江苏康缘集团有限责任公司                      26.94%    111,986,868   3,447,289       108,539,579        无
                               有法人
连云港康贝尔医疗器械有限       境内非国
                                               5.23%    22,132,338               0              0        无
公司                           有法人
招商银行股份有限公司-光
大保德信优势配置股票型证         其他          3.15%    13,083,867    3,849,479                 0       未知
券投资基金
                                  境内
肖   伟                                        2.84%    11,808,082               0              0        无
                                自然人
中国工商银行-博时精选股
                               其他       2.84%   11,800,000 11,800,000                         0       未知
票证券投资基金
中国平安人寿保险股份有限
                               其他       2.69%   11,170,175   1,662,751                        0       未知
公司-传统-普通保险产品
中国平安财产保险股份有限
                               其他       2.27%    9,455,943   2,583,794                        0       未知
公司-传统-普通保险产品
中国农业银行-长城安心回
                               其他       1.92%    8,000,000 -5,000,000                         0       未知
报混合型证券投资基金
中国太平洋人寿保险股份有
限公司-传统-普通保险产       其他       1.61%    6,695,906     995,918                        0       未知

中国建设银行-长城消费增
                               其他       1.35%    5,610,523           0                        0       未知
值股票型证券投资基金
前十名无限售条件股东持股情况
                      股东名称                       持有无限售条件股份的数量               股份种类及数量
连云港康贝尔医疗器械有限公司                                       22,132,338                 人民币普通股
招商银行股份有限公司-光大保德信优势配置股票型证券
                                                                   13,083,867                人民币普通股
投资基金
肖 伟                                                              11,808,082                人民币普通股


                                                第 3 页 共 20 页
             江苏康缘药业股份有限公司 (股票代码:600557)                      2012 年半年度报告摘要


中国工商银行-博时精选股票证券投资基金                                     11,800,000      人民币普通股
中国平安人寿保险股份有限公司-传统-普通保险产品                           11,170,175      人民币普通股
中国平安财产保险股份有限公司-传统-普通保险产品                             9,455,943     人民币普通股
中国农业银行-长城安心回报混合型证券投资基金                                 8,000,000     人民币普通股
中国太平洋人寿保险股份有限公司-传统-普通保险产品                           6,695,906     人民币普通股
中国建设银行-长城消费增值股票型证券投资基金                                 5,610,523     人民币普通股
中国工商银行-建信优选成长股票型证券投资基金                                 4,916,435     人民币普通股
                                                                 前十大股东中,江苏康缘集团有限责任公司和肖
                                                             伟先生存在关联关系,肖伟先生为江苏康缘集团有限
                                                             责任公司第一大股东。公司未知其他股东之间、其他
上述股东关联关系或一致行动的说明
                                                             股东与前十名无限售条件股东之间是否存在关联关系
                                                             或一致行动人关系;公司未知前十名无限售条件股东
                                                             之间是否存在关联关系或一致行动人关系。

              3.3 控股股东及实际控制人变更情况
              □适用 √不适用


         §4 董事、监事和高级管理人员情况

              4.1 董事、监事和高级管理人员持股变动
              √适用 □不适用
                                                                                                单位:股
                                  年初持     本期减持                                       被授予的限制
            姓名        职务                                期末持股数       变动原因
                                    股数     股份数量                                         性股票数量
                       常 务                                                公司终止实施
            郭传宝                500,000       500,000               0                           500,000
                     副总经理                                               股权激励计划
            王振中   副总经理     400,000       400,000               0         同上              400,000
            杨永春   副总经理     350,000       350,000               0         同上              350,000
            刘五生   副总经理     350,000       350,000               0         同上              350,000
            陈友龙   财务总监     200,000       200,000               0         同上              200,000



         §5 董事会报告

              5.1 主营业务分行业、产品情况表

                                                                                 单位:元 币种:人民币
                                                              营业收入       营业成本
 分行业或                                         营业利                                 营业利润率比上年同
               营业收入           营业成本                    比上年同       比上年同
   分产品                                         润率(%)                                     期增减(%)
                                                              期增减(%)      期增减(%)
 分行业
 医药工业 831,916,410.01       183,993,725.94        77.88          20.13         -0.89    增加 4.69 个百分点
 分产品(母公司)
   胶 囊   287,750,295.62       79,576,171.09        72.35         -15.87        -15.45    减少 0.13 个百分点
   注射液  368,777,977.72       71,185,150.30        80.70         102.75         46.61    增加 7.39 个百分点
   片丸剂    20,943,249.96      16,576,683.05        20.85          16.73         -1.72    增加 14.86 个百分点
   口服液    19,147,644.45       3,970,718.61        79.26          53.22         24.79    增加 4.72 个百分点


                                                第 4 页 共 20 页
            江苏康缘药业股份有限公司 (股票代码:600557)                       2012 年半年度报告摘要


颗粒剂
             2,393,409.94       1,154,480.42         51.76        -40.96        -62.45   增加 27.60 个百分点
冲 剂

             其中:报告期内上市公司向控股股东全资子公司连云港康缘医药商业有限公司销售产品
         的关联交易总金额 2041.92 万元。

             5.2 主营业务分地区情况

                                                                                单位:元 币种:人民币
                地 区                          营业收入                         营业收入比上年增减(%)
                华东地区                           365,084,679.84                                           53.21
                华南地区                           107,507,980.03                                           57.41
                华中地区                            70,983,416.58                                            1.39
                华北地区                            55,409,075.70                                          -15.18
                东北地区                            40,081,004.37                                            0.24
                西南地区                            36,437,263.26                                          -40.02
                西北地区                            23,509,157.91                                           49.30

             5.3 主营业务及其结构发生重大变化的原因说明
             □适用 √不适用

             5.4 主营业务盈利能力(毛利率)与上年相比发生重大变化的原因说明
             □适用 √不适用

             5.5 利润构成与上年度相比发生重大变化的原因分析
             □适用 √不适用

             5.6 募集资金使用情况

             5.6.1 募集资金运用
             √适用 □不适用
                                                                                 单位:元 币种:人民币
                                                             本报告期已使用
                                                                                                   29,102,356.71
                                                               募集资金总额
           募集资金总额             282,456,989.24
                                                                 已累计使用
                                                                                                  252,963,123.82
                                                               募集资金总额

                                                                           单位:万元 币种:人民币
                             是否变       拟投入       实际投入      是否符合
             承诺项目                                                           预计收益      产生收益情况
                             更项目         金额         金额        计划进度
         现代中药注射剂
         生产线技术改造        否       15,188.00      16,056.65           是                           6,600.41
         项目
         散结镇痛胶囊产
                               否        6,268.00       3,020.52           否                           未完工
         业化项目
         创新中药研究与
                                                                                                        该项目已
         (GLP)安全评价       是        8,260.00       8,260.00           否
                                                                                                        终止实施
         中心项目
               合 计            /       29,716.00      27,337.17           /                               /




                                               第 5 页 共 20 页
   江苏康缘药业股份有限公司 (股票代码:600557)                 2012 年半年度报告摘要


   5.6.2 更项目情况
   √适用 □不适用
                                                                  单位:万元 币种:人民币
变更投资项目资金总额                                                                   8,260.00
  变更后的                                                   变更项目拟 实际投入       是否符合
                       对应的原承诺项目
  项目名称                                                     投入金额       金额     计划进度
补充流动资金 创新中药研究与(GLP)安全评价中心项目               8,260.00 8,260.00         是
    合 计                      /                                 8,260.00 8,260.00         /


    5.7 非募集资金项目情况
                                                                 单位:万元 币种:人民币
              项目名称                             项目金额             项目进度
              行政办公楼                                 2,105.66               89.60%
              培训中心                                     283.60               14.18%
            中试研发平台                                 3,176.51               73.02%
              质检综合楼                                 1,777.29               63.38%
          北京研发总部装修                               1,001.93               91.92%
        上市品种再评价研发中心                             685.53               14.02%
        康缘弘道软胶囊生产线                              6917.31               14.41%
        康缘医药产业园配套设施                           4,557.58               45.30%
                合 计                                  20,505.41             /


   5.8 董事会下半年的经营计划修改计划
   □适用 √不适用

    5.9 预测年初至下一报告期期末的累计净利润可能为亏损或者与上年同期相比发生大
幅度变动的警示及说明
    □适用 √不适用

   5.10 公司董事会对会计师事务所本报告期“非标准审计报告”的说明
   □适用 √不适用

    5.11 公司董事会对会计师事务所上年度“非标准审计报告”涉及事项的变化及处理情
况的说明
    □适用 √不适用



§6 重要事项

   6.1 收购资产
   □适用 √不适用

    6.2 出售资产

   □适用    √不适用

    6.3 担保事项


                                     第 6 页 共 20 页
江苏康缘药业股份有限公司 (股票代码:600557)        2012 年半年度报告摘要


□适用    √不适用

6.4 关联债权债务往来

□适用    √不适用

6.5 重大诉讼仲裁事项

□适用    √不适用

6.6 其他重大事项及其影响和解决方案的分析说明

6.6.1 证券投资情况
□适用 √不适用

6.6.2 持有其他上市公司股权情况
□适用 √不适用

6.6.3 持有非上市金融企业股权情况
□适用 √不适用




                                  第 7 页 共 20 页
   江苏康缘药业股份有限公司 (股票代码:600557)                      2012 年半年度报告摘要



§7 财务会计报告

7.1 审计意见
财务报告               √未经审计                            □审计

7.2 财务报表
                             合并资产负债表(一)
                               2012 年 6 月 30 日
编制单位:江苏康缘药业股份有限公司
                                                                       单位:元 币种:人民币
               项目                    附注               期末余额               年初余额
流动资产:
货币资金                             五(一)             262,222,946.85           201,714,625.85
交易性金融资产                       五(二)                                        1,000,000.00
应收票据                             五(三)             385,583,993.63           430,108,396.29
应收账款                             五(四)             755,764,019.93           651,454,027.55
预付款项                             五(五)             244,857,810.45           197,776,217.36
其他应收款                           五(六)              64,965,147.48            48,450,680.85
存货                                 五(七)              49,627,215.68            64,605,037.90
其他流动资产
流动资产合计                                            1,763,021,134.02        1,595,108,985.80
非流动资产:
长期股权投资                         五(八)               4,001,167.19             3,997,631.06
固定资产                             五(九)             544,700,202.39           560,670,864.24
在建工程                             五(十)             247,604,237.71           236,886,084.24
工程物资
固定资产清理
生产性生物资产
油气资产
无形资产                            五(十一)            117,190,104.86           101,349,827.53
开发支出                            五(十二)             20,600,000.00            20,600,000.00
商誉                                五(十三)             58,988,858.14            58,988,858.14
长期待摊费用                        五(十四)                445,921.61               445,921.61
递延所得税资产                      五(十五)              3,713,969.96             3,358,432.07
其他非流动资产
非流动资产合计                                            997,244,461.86          986,297,618.89
资产总计                                                2,760,265,595.88        2,581,406,604.69

法定代表人:肖伟          主管会计工作负责人:陈友龙             会计机构负责人:焦晓杉




                                     第 8 页 共 20 页
   江苏康缘药业股份有限公司 (股票代码:600557)                     2012 年半年度报告摘要


                             合并资产负债表(二)
                               2012 年 6 月 30 日
编制单位:江苏康缘药业股份有限公司
                                                                      单位:元 币种:人民币
             项目                     附注五              期末余额              年初余额
流动负债:
短期借款                             (十七)             457,000,000.00          466,420,000.00
应付票据                             (十八)              83,000,000.00          120,000,000.00
应付账款                             (十九)             138,011,529.41          126,301,409.26
预收款项                             (二十)              20,044,821.26           28,973,348.05
应付手续费及佣金
应付职工薪酬                       (二十一)              6,601,431.42             6,318,701.55
应交税费                           (二十二)             43,205,900.72            21,066,522.58
应付利息                           (二十三)                822,081.37             1,036,726.43
应付股利                                                   6,958,430.14               852,728.41
其他应付款                                               186,865,110.39           161,354,504.69
其他流动负债                       (二十五)             32,358,866.09            22,976,582.81
流动负债合计                                             974,868,170.80           955,300,523.78
非流动负债:
长期借款                           (二十六)             263,000,000.00          148,000,000.00
应付债券
长期应付款
专项应付款                         (二十七)               7,326,346.00            3,278,438.00
其他非流动负债
非流动负债合计                                            270,326,346.00         151,278,438.00
负债合计                                                1,245,194,516.80       1,106,578,961.78
所有者权益(或股东权益):
实收资本(或股本)                 (二十八)             415,646,691.00          423,246,691.00
资本公积                           (二十九)             268,152,669.08          300,041,256.29
减:库存股
专项储备
盈余公积                             (三十)             117,993,352.67          117,993,352.67
一般风险准备
未分配利润                         (三十一)             673,895,422.00         595,364,665.27
外币报表折算差额                                             -769,083.67            -773,156.40
归属于母公司所有者权益合计                              1,474,919,051.08       1,435,872,808.83
少数股东权益                                               40,152,028.00          38,954,834.08
所有者权益合计                                          1,515,071,079.08       1,474,827,642.91
负债和所有者权益总计                                    2,760,265,595.88       2,581,406,604.69



法定代表人:肖伟          主管会计工作负责人:陈友龙             会计机构负责人:焦晓杉




                                     第 9 页 共 20 页
   江苏康缘药业股份有限公司 (股票代码:600557)                     2012 年半年度报告摘要


                             母公司资产负债表 (一)
                                 2012 年 6 月 30 日
编制单位:江苏康缘药业股份有限公司
                                                                      单位:元 币种:人民币
              项目                   附注十二             期末余额              年初余额
流动资产:
货币资金                                                  210,565,898.60         146,727,209.10
交易性金融资产                                                                     1,000,000.00
应收票据                                                  348,343,117.05         381,907,832.38
应收账款                              (一)              653,737,349.43         553,986,029.41
预付款项                                                  140,497,128.44         141,229,785.61
其他应收款                            (二)               18,866,964.43          15,658,131.83
存货                                                       27,993,614.00          47,214,394.83
一年内到期的非流动资产
其他流动资产
流动资产合计                                            1,400,004,071.95       1,287,723,383.16
非流动资产:
长期股权投资                          (三)              190,877,362.86         190,873,826.73
投资性房地产
固定资产                                                  510,025,200.77         525,756,892.44
在建工程                                                  175,800,894.17         155,726,938.31
工程物资
固定资产清理
无形资产                                                   76,031,732.77           76,785,428.36
开发支出                                                   20,600,000.00           20,600,000.00
商誉
递延所得税资产                                              1,786,227.18            1,591,569.12
其他非流动资产
非流动资产合计                                            975,121,417.75         971,334,654.96
资产总计                                                2,375,125,489.70       2,259,058,038.12

法定代表人:肖伟          主管会计工作负责人:陈友龙              会计机构负责人:焦晓杉




                                    第 10 页 共 20 页
   江苏康缘药业股份有限公司 (股票代码:600557)                     2012 年半年度报告摘要


                             母公司资产负债表 (二)
                                 2012 年 6 月 30 日
编制单位:江苏康缘药业股份有限公司
                                                                      单位:元 币种:人民币
              项目                      附注              期末余额              年初余额
流动负债:
短期借款                                                  347,000,000.00         367,000,000.00
交易性金融负债
应付票据                                                   50,000,000.00         100,000,000.00
应付账款                                                  103,964,830.11          97,827,270.17
预收款项                                                   17,728,177.52          26,375,303.30
应付职工薪酬                                                4,668,988.05           4,347,931.37
应交税费                                                   35,920,571.35          12,447,574.98
应付利息                                                      677,938.71             873,767.28
应付股利                                                    6,512,374.74
其他应付款                                                121,071,767.42         121,764,489.53
一年内到期的非流动负债
其他流动负债                                              32,358,866.09           22,976,582.81
流动负债合计                                             719,903,513.99          753,612,919.44
非流动负债:
长期借款                                                  193,000,000.00           78,000,000.00
应付债券
长期应付款
专项应付款                                                  3,026,346.00            3,278,438.00
预计负债
递延所得税负债
其他非流动负债
非流动负债合计                                           196,026,346.00           81,278,438.00
负债合计                                                 915,929,859.99          834,891,357.44
所有者权益(或股东权益):
实收资本(或股本)                                        415,646,691.00         423,246,691.00
资本公积                                                  268,152,669.08         300,041,256.29
减:库存股
专项储备
盈余公积                                                  116,186,192.11         116,186,192.11
一般风险准备
未分配利润                                                659,210,077.52         584,692,541.28
所有者权益合计                                          1,459,195,629.71       1,424,166,680.68
负债和所有者权益总计                                    2,375,125,489.70       2,259,058,038.12

法定代表人:肖伟          主管会计工作负责人:陈友龙              会计机构负责人:焦晓杉




                                    第 11 页 共 20 页
   江苏康缘药业股份有限公司 (股票代码:600557)               2012 年半年度报告摘要


                                       合并利润表
                                     2012 年 1—6 月
                                                                单位:元 币种:人民币
                   项目                        附注五       本期金额          上期金额
一、营业总收入                                            833,883,482.13    736,548,835.27
其中:营业收入                               (三十二)   833,883,482.13    736,548,835.27
手续费及佣金收入
二、营业总成本                                            717,596,607.63      625,219,920.40
其中:营业成本                               (三十二)   184,209,059.60      224,161,965.51
分保费用
营业税金及附加                               (三十三)    14,114,853.45       10,879,248.77
销售费用                                     (三十四)   344,758,425.29      281,529,611.28
管理费用                                     (三十五)   147,013,413.47       88,646,663.14
财务费用                                     (三十六)    25,984,108.25       18,075,272.71
资产减值损失                                 (三十七)     1,516,747.57        1,927,158.99
投资收益(损失以“-”号填列)               (三十八)        49,695.03            5,156.33
其中:对联营企业和合营企业的投资收益
汇兑收益(损失以“-”号填列)
三、营业利润(亏损以“-”号填列)                        116,336,569.53      111,334,071.20
加:营业外收入                               (三十九)     7,059,283.55        5,731,702.40
减:营业外支出                               (四十)         658,570.25           63,555.32
其中:非流动资产处置损失                                      267,109.43           57,005.32
对外捐赠                                                      100,000.00            5,000.00
其他                                                              750.00              750.00
基金费用                                                      290,710.82              800.00
四、利润总额(亏损总额以“-”号填列)                    122,737,282.83      117,002,218.28
减:所得税费用                               (四十一)    18,070,530.72       17,637,708.51
五、净利润(净亏损以“-”号填列)                        104,666,752.11       99,364,509.77
归属于母公司所有者的净利润                                103,469,558.19       96,715,431.24
少数股东损益                                                1,197,193.92        2,649,078.53
六、每股收益:
(一)基本每股收益                           (四十二)             0.25                0.23
(二)稀释每股收益                           (四十二)             0.25                0.23
七、其他综合收益
八、综合收益总额                                          104,666,752.11       99,364,509.77
归属于母公司所有者的综合收益总额                          103,469,558.19       96,715,431.24
归属于少数股东的综合收益总额

法定代表人:肖伟          主管会计工作负责人:陈友龙         会计机构负责人:焦晓杉




                                    第 12 页 共 20 页
   江苏康缘药业股份有限公司 (股票代码:600557)              2012 年半年度报告摘要


                                      母公司利润表
                                     2012 年 1—6 月
                                                                单位:元 币种:人民币
                   项目                       附注十一     本期金额           上期金额
一、营业收入                                    (四)   700,979,649.81     559,199,903.26
    减:营业成本                                (四)   172,678,537.13     166,009,660.88
        营业税金及附加                                    11,499,652.72       8,504,568.27
        销售费用                                         258,805,142.03     201,686,662.25
        管理费用                                         125,340,726.88      63,700,736.27
        财务费用                                          21,122,754.01      15,076,854.15
        资产减值损失                                       1,299,351.37       1,258,416.91
        投资收益(损失以“-”号填列)                         49,695.03      3,797,756.33
二、营业利润(亏损以“-”号填列)                       110,283,180.70     106,760,760.86
    加:营业外收入                                         6,993,516.72       3,548,494.70
    减:营业外支出                                           498,250.78           55,388.25
        其中:非流动资产处置损失
三、利润总额(亏损总额以“-”号填列)                   116,778,446.64      110,253,867.31
    减:所得税费用                                        17,322,108.94       16,220,596.40
四、净利润(净亏损以“-”号填列)                        99,456,337.70       94,033,270.91
五、每股收益:
    (一)基本每股收益                                             0.24                0.22
    (二)稀释每股收益                                             0.24                0.22
六、其他综合收益
七、综合收益总额                                          99,456,337.70       94,033,270.91

法定代表人:肖伟          主管会计工作负责人:陈友龙        会计机构负责人:焦晓杉




                                    第 13 页 共 20 页
   江苏康缘药业股份有限公司 (股票代码:600557)                2012 年半年度报告摘要


                                    合并现金流量表
                                    2012 年 1—6 月
                                                                  单位:元 币种:人民币
                项目                           附注五       本期金额           上期金额
一、经营活动产生的现金流量:
销售商品、提供劳务收到的现金                              901,454,121.87      691,735,123.21
收到的税费返还                                                                  4,089,538.05
收到其他与经营活动有关的现金                 (四十二)    62,888,783.72       32,025,048.10
经营活动现金流入小计                                      964,342,905.59      727,849,709.36
购买商品、接受劳务支付的现金                              180,266,108.67      167,028,861.70
支付给职工以及为职工支付的现金                            144,881,150.84      124,036,777.45
支付的各项税费                                            143,087,038.68      118,974,143.08
支付其他与经营活动有关的现金                              392,162,704.72      307,757,399.98
经营活动现金流出小计                                      860,397,002.91      717,797,182.21
经营活动产生的现金流量净额                                103,945,902.68       10,052,527.15
二、投资活动产生的现金流量:
收回投资收到的现金                                          1,000,000.00
取得投资收益收到的现金                                         46,158.90
处置固定资产、无形资产和其他长期资产
                                                           32,892,155.00           113,175.00
收回的现金净额
收到其他与投资活动有关的现金                                4,300,000.00            25,770.48
投资活动现金流入小计                                       38,238,313.90           138,945.48
购建固定资产、无形资产和其他长期资产
                                                           98,695,993.93      108,295,552.81
支付的现金
投资支付的现金                                                                  5,000,000.00
投资活动现金流出小计                                       98,695,993.93      113,295,552.81
投资活动产生的现金流量净额                                -60,457,680.03     -113,156,607.33
三、筹资活动产生的现金流量:
吸收投资收到的现金                                        -63,308,000.00       63,308,000.00
取得借款收到的现金                                        435,500,000.00      295,722,872.50
收到其他与筹资活动有关的现金                                                   18,019,146.58
筹资活动现金流入小计                                      372,192,000.00      377,050,019.08
偿还债务支付的现金                                        317,420,000.00      209,566,505.42
分配股利、利润或偿付利息支付的现金                         37,755,483.91       26,836,790.23
支付其他与筹资活动有关的现金
筹资活动现金流出小计                                      355,175,483.91      236,403,295.65
筹资活动产生的现金流量净额                                 17,016,516.09      140,646,723.43
四、汇率变动对现金及现金等价物的影响                            3,582.26           49,580.21
五、现金及现金等价物净增加额                               60,508,321.00       37,592,223.46
加:期初现金及现金等价物余额                              201,714,625.85      151,523,396.75
六、期末现金及现金等价物余额                              262,222,946.85      189,115,620.21

法定代表人:肖伟          主管会计工作负责人:陈友龙          会计机构负责人:焦晓杉




                                    第 14 页 共 20 页
   江苏康缘药业股份有限公司 (股票代码:600557)              2012 年半年度报告摘要


                                   母公司现金流量表
                                     2012 年 1—6 月
                                                               单位:元 币种:人民币
                  项目                             附注    本期金额           上期金额
一、经营活动产生的现金流量:
销售商品、提供劳务收到的现金                              742,591,935.14       518,005,492.86
收到其他与经营活动有关的现金                               57,434,932.57         7,056,010.58
经营活动现金流入小计                                      800,026,867.71       525,061,503.44
购买商品、接受劳务支付的现金                              161,856,183.49       110,195,259.07
支付给职工以及为职工支付的现金                            111,656,840.22        96,686,708.04
支付的各项税费                                            115,350,959.26        93,886,687.20
支付其他与经营活动有关的现金                              308,215,666.03       207,477,888.36
经营活动现金流出小计                                      697,079,649.00       508,246,542.67
经营活动产生的现金流量净额                                102,947,218.71        16,814,960.77
二、投资活动产生的现金流量:
收回投资收到的现金                                          1,000,000.00
取得投资收益收到的现金                                         46,158.90
处置固定资产、无形资产和其他长期资产收回
                                                           32,892,155.00              113,175.00
的现金净额
处置子公司及其他营业单位收到的现金净额
收到其他与投资活动有关的现金
投资活动现金流入小计                                       33,938,313.90              113,175.00
购建固定资产、无形资产和其他长期资产支付
                                                           74,043,036.46        73,238,287.00
的现金
投资支付的现金                                                                   5,000,000.00
支付其他与投资活动有关的现金
投资活动现金流出小计                                       74,043,036.46        78,238,287.00
投资活动产生的现金流量净额                                -40,104,722.56       -78,125,112.00
三、筹资活动产生的现金流量:
吸收投资收到的现金                                        -63,308,000.00        63,308,000.00
取得借款收到的现金                                        373,000,000.00       244,000,000.00
筹资活动现金流入小计                                      309,692,000.00       307,308,000.00
偿还债务支付的现金                                        278,000,000.00       171,000,000.00
分配股利、利润或偿付利息支付的现金                         30,695,806.65        23,305,434.46
支付其他与筹资活动有关的现金
筹资活动现金流出小计                                      308,695,806.65       194,305,434.46
筹资活动产生的现金流量净额                                    996,193.35       113,002,565.54
四、汇率变动对现金及现金等价物的影响
五、现金及现金等价物净增加额                               63,838,689.50        51,692,414.31
加:期初现金及现金等价物余额                              146,727,209.10       106,838,320.05
六、期末现金及现金等价物余额                              210,565,898.60       158,530,734.36

法定代表人:肖伟          主管会计工作负责人:陈友龙       会计机构负责人:焦晓杉




                                    第 15 页 共 20 页
       江苏康缘药业股份有限公司 (股票代码:600557)                                                                              2012 年半年度报告摘要


                                                                    合并所有者权益变动表
                                                                        2012 年 1—6 月
                                                                                                                                     单位:元 币种:人民币
                                                                                       本期金额
           项目                                                归属于母公司所有者权益
                                  实收资本            资本公积         盈余公积        未分配利润             其他        少数股东权益       所有者权益合计
一、上年年末余额               423,246,691.00      300,041,256.29    117,993,352.67   595,364,665.27       -773,156.40    38,954,834.08      1,474,827,642.91
加:会计政策变更
二、本年年初余额               423,246,691.00      300,041,256.29    117,993,352.67       595,364,665.27   -773,156.40    38,954,834.08      1,474,827,642.91
三、本期增减变动金额            -7,600,000.00      -31,888,587.21                          78,530,756.73      4,072.73     1,197,193.92         40,243,436.17
(一)净利润                                                                              103,469,558.19                   1,197,193.92        104,666,752.11
(二)其他综合收益
上述(一)和(二)小计                                                                    103,469,558.19                    1,197,193.92       104,666,752.11
(三)所有者投入和减少资本       -7,600,000.00     -31,888,587.21                                             4,072.73                         -39,484,514.48
2.股份支付计入所有者权益
                                 -7,600,000.00     -31,888,587.21                                                                              -39,488,587.21
的金额
3.其他                                                                                                       4,072.73                               4,072.73
(四)利润分配                                                                            -24,938,801.46                                       -24,938,801.46
3.对所有者的分配                                                                         -24,938,801.46                                       -24,938,801.46
(五)所有者权益内部结转
(六)专项储备
(七)其他
四、本期期末余额               415,646,691.00      268,152,669.08    117,993,352.67       673,895,422.00   -769,083.67    40,152,028.00      1,515,071,079.08

   法定代表人:肖伟                                         主管会计工作负责人:陈友龙                                   会计机构负责人:焦晓杉




                                                                      第 16 页 共 20 页
       江苏康缘药业股份有限公司 (股票代码:600557)                                                                                 2012 年半年度报告摘要


                                                                                            上年同期金额
           项目                                                归属于母公司所有者权益
                                  实收资本            资本公积         盈余公积        未分配利润                其他        少数股东权益       所有者权益合计
一、上年年末余额               415,646,691.00      238,318,072.13    100,134,392.44   455,654,287.57          -579,640.10    35,120,020.97      1,244,293,824.01
加:会计政策变更
二、本年年初余额               415,646,691.00      238,318,072.13      100,134,392.44       455,654,287.57    -579,640.10    35,120,020.97      1,244,293,824.01
三、本期增减变动金额             7,600,000.00       61,723,184.16       17,858,960.23       139,710,377.70    -193,516.30     3,834,813.11        230,533,818.90
(一)净利润                                                                                182,508,139.39                    6,953,593.70        189,461,733.09
(二)其他综合收益
上述(一)和(二)小计                                                                       182,508,139.39                    6,953,593.70       189,461,733.09
(三)所有者投入和减少资本        7,600,000.00         61,723,184.16                                          -193,516.30     -3,118,780.59        66,010,887.27
1.所有者投入资本                                                                                                               -324,064.59          -324,064.59
2.股份支付计入所有者权益
                                  7,600,000.00         61,723,184.16                                                                               69,323,184.16
的金额
3.其他                                                                                                       -193,516.30     -2,794,716.00        -2,988,232.30
(四)利润分配                                                          17,858,960.23        -42,797,761.69                                       -24,938,801.46
1.提取盈余公积                                                         17,858,960.23        -17,858,960.23
3.对所有者的分配                                                                            -24,938,801.46                                       -24,938,801.46
(五)所有者权益内部结转
(六)专项储备
(七)其他
四、本期期末余额               423,246,691.00      300,041,256.29      117,993,352.67       595,364,665.27    -773,156.40    38,954,834.08      1,474,827,642.91

   法定代表人:肖伟                                            主管会计工作负责人:陈友龙                                   会计机构负责人:焦晓杉




                                                                        第 17 页 共 20 页
   江苏康缘药业股份有限公司 (股票代码:600557)                                                                             2012 年半年度报告摘要


                                                                    母公司所有者权益变动表
                                                                        2012 年 1—6 月
                                                                                                                                单位:元 币种:人民币
                                                                                                本期金额
                    项目                              实收资本          资本公积             盈余公积        未分配利润      所有者权益合计
    一、上年年末余额                               423,246,691.00     300,041,256.29       116,186,192.11   584,692,541.28   1,424,166,680.68
    加:会计政策变更
    二、本年年初余额                               423,246,691.00     300,041,256.29       116,186,192.11   584,692,541.28    1,424,166,680.68
    三、本期增减变动金额                            -7,600,000.00     -31,888,587.21                         74,517,536.24       35,028,949.03
    (一)净利润                                                                                             99,456,337.70       99,456,337.70
    (二)其他综合收益
    上述(一)和(二)小计                                                                                   99,456,337.70       99,456,337.70
    (三)所有者投入和减少资本                      -7,600,000.00     -31,888,587.21                                            -39,488,587.21
    1.所有者投入资本
    2.股份支付计入所有者权益的金额                 -7,600,000.00     -31,888,587.21                                            -39,488,587.21
    (四)利润分配                                                                                          -24,938,801.46      -24,938,801.46
    1.提取盈余公积
    2.提取一般风险准备
    3.对所有者(或股东)的分配                                                                             -24,938,801.46      -24,938,801.46
    (五)所有者权益内部结转
    (六)专项储备
    (七)其他
    四、本期期末余额                               415,646,691.00     268,152,669.08       116,186,192.11   659,210,077.52    1,459,195,629.71

法定代表人:肖伟                                           主管会计工作负责人:陈友龙                               会计机构负责人:焦晓杉




                                                                       第 18 页 共 20 页
   江苏康缘药业股份有限公司 (股票代码:600557)                                                                            2012 年半年度报告摘要




                                                                                            上年同期金额
                                                      实收资本        资本公积             盈余公积         未分配利润      所有者权益合计
    一、上年年末余额                               415,646,691.00   238,318,072.13        98,327,231.88    448,900,700.64   1,201,192,695.65
    加:会计政策变更
    二、本年年初余额                               415,646,691.00   238,318,072.13        98,327,231.88    448,900,700.64    1,201,192,695.65
    三、本期增减变动金额                             7,600,000.00    61,723,184.16        17,858,960.23    135,791,840.64      222,973,985.03
    (一)净利润                                                                                           178,589,602.33      178,589,602.33
    (二)其他综合收益
    上述(一)和(二)小计                                                                                 178,589,602.33      178,589,602.33
    (三)所有者投入和减少资本                       7,600,000.00    61,723,184.16                                              69,323,184.16
    1.所有者投入资本
    2.股份支付计入所有者权益的金额                  7,600,000.00    61,723,184.16                                              69,323,184.16
    (四)利润分配                                                                        17,858,960.23    -42,797,761.69      -24,938,801.46
    1.提取盈余公积                                                                       17,858,960.23    -17,858,960.23
    2.提取一般风险准备
    3.对所有者(或股东)的分配                                                                            -24,938,801.46      -24,938,801.46
    (五)所有者权益内部结转
    (六)专项储备
    (七)其他
    四、本期期末余额                               423,246,691.00   300,041,256.29       116,186,192.11    584,692,541.28    1,424,166,680.68

法定代表人:肖伟                                           主管会计工作负责人:陈友龙                              会计机构负责人:焦晓杉




                                                                     第 19 页 共 20 页
   江苏康缘药业股份有限公司 (股票代码:600557)                      2012 年半年度报告摘要



    7.3 本报告期无会计政策、会计估计的变更。
    7.4 本报告期无前期会计差错更正。
    7.5 企业合并及合并财务报表
    7.6 境外经营实体主要报表项目的折算汇率
     资产负债表中的资产和负债项目,采用资产负债表日的即期汇率折算;所有者权益项目除"未分配
利润"项目外,其他项目采用发生时的即期汇率折算。利润表中的收入和费用项目,采用交易发生日的
即期汇率折算。按照上述折算产生的外币财务报表折算差额,在资产负债表所有者权益项目下单独列
示。




                                         第 20 页 共 20 页

相关新闻